Artes Biotechnology GmbH-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Artes Biotechnology GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010842
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Artes Biotechnology GmbH (ARTES) is a developer of recombinant production cell lines and processes that is based on the microbial expression platforms. The company offers biosimilars, enzymes and proteins and vaccines. It offers technology transfer and implementation support, protein analytics, and manufacturing of preclinical and clinical material. ARTES offers research and development contract services to develop the targets of client’s choice and transfers in house developed cell lines and processes for vaccines, bio pharmaceuticals, cosmetics, veterinary, bio similars and enzymes. The company utilizes its hansenula polymorpha and metavax platforms to offer its services. ARTES is headquartered in Langenfeld, Germany.

Artes Biotechnology GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ARTES Biotech to Enter into Co-Development Agreement with Biosun Pharmed 10
Artes Biotechnology Enters into Agreement with Burnet Institute 11
Artes Biotech Enters into Co-Development Agreement with Burnet Institute 12
Artes Biotech Enters Into Agreement With Bio Farma For Vaccine Development 13
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 14
Artes Biotech Enters Into Co-Marketing Agreement With NL Biotech 15
Artes Biotechnology GmbH – Key Competitors 16
Artes Biotechnology GmbH – Key Employees 17
Artes Biotechnology GmbH – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Other Significant Developments 19
Feb 19, 2016: ARTES offers manufacturing of preclinical samples up to multi-gram scale 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Artes Biotechnology GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
Artes Biotechnology GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ARTES Biotech to Enter into Co-Development Agreement with Biosun Pharmed 10
Artes Biotechnology Enters into Agreement with Burnet Institute 11
Artes Biotech Enters into Co-Development Agreement with Burnet Institute 12
Artes Biotech Enters Into Agreement With Bio Farma For Vaccine Development 13
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 14
Artes Biotech Enters Into Co-Marketing Agreement With NL Biotech 15
Artes Biotechnology GmbH, Key Competitors 16
Artes Biotechnology GmbH, Key Employees 17

★海外企業調査レポート[Artes Biotechnology GmbH-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NanoSmart Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary NanoSmart Pharmaceuticals Inc (NanoSmart) focuses on the development of novel methods for the treatment of cancer and other diseases. The company is evaluating a human-derived anti-nuclear antibody which targets areas of necrosis presence in various different types of cancer tumors. Its prop …
  • Sandoz Inc-製薬・医療分野:企業M&A・提携分析
    Summary Sandoz Inc (Sandoz), a division of Novartis AG, is a generic pharmaceutical company that develops, manufactures and distributes and sells a range of prescription medicines and protein and biotechnology-based products known as biosimilars. The company also provides intermediary products inclu …
  • IMPARAT Farbwerk Iversen & Mahl GmbH & Co KG:企業の戦略・SWOT・財務情報
    IMPARAT Farbwerk Iversen & Mahl GmbH & Co KG - Strategy, SWOT and Corporate Finance Report Summary IMPARAT Farbwerk Iversen & Mahl GmbH & Co KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Harte Hanks Inc (HHS):企業の財務・戦略的SWOT分析
    Harte Hanks Inc (HHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Swissport Tanzania Limited:企業の戦略・SWOT・財務分析
    Swissport Tanzania Limited - Strategy, SWOT and Corporate Finance Report Summary Swissport Tanzania Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • TAS Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary TAS Energy, Inc. (TAS), formerly Turbine Air Systems, Ltd., offers clean and modular energy solutions. The company designs, manufactures and supplies turbine inlet chilling systems for power augmentation; modular utility systems for air cooling; waste heat/geothermal systems for power genera …
  • Magnit:企業の戦略・SWOT・財務情報
    Magnit - Strategy, SWOT and Corporate Finance Report Summary Magnit - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • MLM Biologics Inc:企業の製品パイプライン分析2018
    Summary MLM Biologics Inc (MLM Biologics) is a medical device company that provides optimum wound care management for patients and doctors. The company’s product includes bio-ConneKt Wound Matrix, a collagen-based wound dressing for chronic vascular ulcers, draining wounds, partial and full thicknes …
  • Sinocare Inc (300298):医療機器:M&Aディール及び事業提携情報
    Summary Sinocare Inc (Sinocare) is a medical device company that focuses on the research, development, manufacturing and commercialization of diagnosis testing products for diabetes and other chronic diseases. Its product portfolio comprises mobile glucose meter, portable automatic biochemical analy …
  • Islandsbanki hf.:企業の戦略・SWOT・財務分析
    Islandsbanki hf. - Strategy, SWOT and Corporate Finance Report Summary Islandsbanki hf. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Polynt SpA:企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Biohaven Pharmaceutical Holding Company Ltd (BHVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that include …
  • Metro AG:企業の戦略・SWOT・財務情報
    Metro AG - Strategy, SWOT and Corporate Finance Report Summary Metro AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • The Scoular Company:戦略・SWOT・企業財務分析
    The Scoular Company - Strategy, SWOT and Corporate Finance Report Summary The Scoular Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Cogent Communications Holdings inc (CCOI):企業の財務・戦略的SWOT分析
    Cogent Communications Holdings inc (CCOI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Icade SA:企業のM&A・事業提携・投資動向
    Icade SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Icade SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • GS Yuasa Corporation:企業の戦略・SWOT・財務分析
    GS Yuasa Corporation - Strategy, SWOT and Corporate Finance Report Summary GS Yuasa Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Electricite de France SA (EDF)-石油・ガス分野:企業M&A・提携分析
    Summary Electricite de France S.A. (EDF) is a state-owned integrated energy company that generates, transmits, distributes and sells electricity; supplies natural gas; and offers energy services such as district heating, thermal energy services and other services. The group generates electricity fro …
  • CRISPR Therapeutics:戦略・SWOT・企業財務分析
    CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report Summary CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Braeburn Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Braeburn Pharmaceuticals Inc (Braeburn), a subsidiary of Apple Tree Partners is a pharmaceutical company that develops novel and long-acting implantable and injectable treatments.The company’s product pipeline includes Probuphine, CAM2038, BB-0417, BB-0817, BB-1216. Its Probuphine, is a a si …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆